Disability

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new…

2 years ago

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),…

2 years ago

German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk"…

2 years ago

AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022

Unique, intra-articular administration of AMB-05X yielded sustained, high synovial concentrations with low systemic exposures and positive clinical efficacyREDWOOD CITY, Calif.,…

2 years ago

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa…

2 years ago

Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today…

2 years ago

TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine

Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment…

2 years ago

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the…

2 years ago

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated…

2 years ago